

IRIDEX CORP  
Form 8-K  
July 09, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported)**

**July 8, 2013**

**IRIDEX CORPORATION**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction)**

**0-27598**  
**(Commission)**

**77-0210467**  
**(IRS Employer)**

Edgar Filing: IRIDEX CORP - Form 8-K

of incorporation)

File Number)  
1212 Terra Bella Avenue

Identification No.)

Mountain View, California 94043

(Address of principal executive offices, including zip code)

(650) 940-4700

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

On July 8, 2013, IRIDEX Corporation (the Company or IRIDEX ) announced that, as part of the Company's on-going management succession planning, Eduardo Arias has transitioned from Senior Vice President, Global Sales to Senior Vice President, Global Affairs. Mr. Arias's new role will be to further develop and strengthen IRIDEX's strategic positioning within the global markets for therapeutic based laser systems, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. Existing members of IRIDEX management team have assumed responsibility, on an interim basis, for the Company's domestic and international sales operations.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IRIDEX CORPORATION**

By: /s/ WILLIAM M. MOORE  
William M. Moore

President and Chief Executive Officer

Date: July 9, 2013